Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-39,200
Closed -$2.16M 3847
2026
Q1
$2.16M Buy
39,200
+34,600
+752% +$1.87M ﹤0.01% 1789
2025
Q4
$226K Sell
4,600
-200
-4% -$9.33K ﹤0.01% 3222
2025
Q3
$207K Sell
4,800
-6,400
-57% -$250K ﹤0.01% 3191
2025
Q2
$430K Buy
+11,200
New +$428K ﹤0.01% 2688
2024
Q4
Sell
-8,700
Closed -$356K 3203
2024
Q3
$356K Buy
+8,700
New +$356K ﹤0.01% 2215

Other funds holding GSK

Paul Tudor Jones's GSK Position: Q2 2023 in Review

Paul Tudor Jones sold out of GSK (GSK) in Q2 2023, closing a stake of 10,816 shares — an estimated $385K sold.

Paul Tudor Jones first reported a position in GSK in Q3 2022 and held it in 2 quarters. The position peaked at $681K in Q3 2022. 828 funds tracked by Wall St. Rank hold GSK as of Q2 2023.

  • Paul Tudor Jones reported no remaining GSK position as of Q2 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 10,816 GSK shares in Q2 2023, an estimated $385K.
  • Paul Tudor Jones first reported a position in GSK in Q3 2022 and held it in 2 quarters.
  • Paul Tudor Jones's GSK position peaked at $681K in Q3 2022.
  • 828 funds tracked by Wall St. Rank held GSK as of Q2 2023.

Based on Tudor Investment Corp's 13F filing for Q2 2023, filed 14 Aug 2023.